Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: A pilot study

European Journal of Surgical Oncology

Volumn 39, Issue 12, 2013, Pages 1364-1370

  Tanaka, K ^a   Yabushita, Y ^a   Nakagawa, K ^a   Kumamoto, T ^a   Matsuo, K ^a   Taguri, M ^a   Endo, I ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Intraarterial chemotherapy; Reduction surgery; Survival

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL;

ADULT; ADVANCED CANCER; ANEURYSM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; FEMORAL ARTERY; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER VEIN; LONG TERM SURVIVAL; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; OVERALL SURVIVAL; PILOT STUDY; PORTAL VEIN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR INVASION;

Α-FETOPROTEIN; 95% CONFIDENCE INTERVAL; AFP; CDDP; CH; CHEMOTHERAPY; CHRONIC HEPATITIS; CI; CISPLATIN; COMPUTED TOMOGRAPHY; CT; CT WITH ARTERIOPORTOGRAPHY; CTAP; CTX; EASTERN COOPERATIVE ONCOLOGY GROUP; ECOG; FLUOROURACIL; FU; GASTROINTESTINAL; GI; HBV; HCC; HCV; HEPATECTOMY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; HX; ICGR15; IFN; INDOCYANINE GREEN RETENTION RATE AT 15 MIN; INTERFERON; INTRAARTERIAL CHEMOTHERAPY; LC; LIVER CIRRHOSIS; NBNC; NL; NON-B VIRAL, NON-C VIRAL; NORMAL LIVER; PIVKA; PREDICTION SCORE; PROTEIN INDUCED BY VITAMIN K ABSENCE; PS; REDUCTION SURGERY; RELATIVE RISK; RR; SURVIVAL; TACE; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; ULTRASONOGRAPHY; US;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR BURDEN;

EID: 84888296034     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.10.007     Document Type: Article

References (35)

1. H. Bismuth, D. Houssin, J. Ornowski, and F. Meriggi Liver resections in cirrhotic patients: a Western experience World J Surg 10 1986 311 317
2. The Liver Cancer Study Group of Japan Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment Ann Surg 211 1990 277 287
3. I. Ikai, S. Arii, and M. Kojiro Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey Cancer 101 2004 796 802
4. Y. Shimamura, P. Gunvén, M. Ishii, M. Ono, and K. Abe Debulking surgery and arterial embolization for unresectable liver cancer Hepatogastroenterology 40 1993 10 13
5. M. Yamamoto, H. Iizuka, M. Matsuda, K. Nagahori, K. Miura, and J. Itakura The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma Surg Today 23 1993 675 681
6. K. Yamamoto, K. Takenaka, and N. Kawahara Indications for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumor index Arch Surg 132 1997 120 123
7. J. Nagashima, K. Okuda, M. Tanaka, M. Sata, and S. Aoyagi Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma - comparison to transcatheter arterial chemoembolization Int J Oncol 15 1999 1117 1123
8. H. Wakabayashi, T. Ushiyama, and K. Ishimura Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions J Surg Oncol 82 2003 98 103
9. Y. Ku, T. Iwasaki, and M. Tominaga Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma Ann Surg 239 2004 53 60
10. K. Inoue, T. Nakamura, and T. Kinoshita Volume reduction surgery for advanced hepatocellular carcinoma J Cancer Res Clin Oncol 130 2004 362 366
11. Y.Z. Patt, B. Yoffe, and C. Charnsangavej Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b Cancer 72 1993 2574 2582
12. T. Urabe, S. Kaneko, E. Matsushita, M. Unoura, and K. Kobayashi Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma Oncology 55 1998 39 47
13. T.W. Leung, Y.Z. Patt, and W.Y. Lau Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma Clin Cancer Res 5 1999 1676 1681
14. Y.H. Chung, I.H. Song, and B.C. Song Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis Cancer 88 2000 1986 1991
15. Y.Z. Patt, M.M. Hassan, and R.D. Lozano Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma J Clin Oncol 21 2003 421 427
16. S. Obi, H. Yoshida, and R. Toune Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion Cancer 106 2006 1990 1997
17. M. Sakon, H. Nagano, and K. Dono Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches Cancer 94 2002 435 442
18. The Brisbane 2000 Terminology of Liver Anatomy and Resection Terminology Committee of the International Hepato-Pancreato-Biliary Association HPB 2 2000 333 339
19. N. Yamanaka, E. Okamoto, and T. Oriyama A prediction scoring system to select the surgical treatment of liver cancer. Further refinement based on 10 years of use Ann Surg 219 1994 342 346
20. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
22. B.K. Kim, J.Y. Park, and H.J. Choi Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma J Cancer Res Clin Oncol 137 2011 659 667
23. N. Urayama, T. Yamasaki, and Y. Harima Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: analysis of 114 cases Kanzo (In Japanese) 52 2011 449 460
24. H. Nagano, H. Wada, and S. Kobayashi Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis Oncology 80 2011 63 69
25. H. Nagano Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon Oncology 78 Suppl. 1 2010 142 147
26. H. Nagano, A. Miyamoto, and H. Wada Interferon-α and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombi in the major trunk, and multiple nodules Cancer 110 2007 2493 2501
27. M. Shimada, K. Takenaka, and N. Kawahara Surgical treatment strategy for patients with stage IV hepatocellular carcinoma Surgery 119 1996 517 522
28. I. Ikai, Y. Yamaoka, and Y. Yamamoto Surgical intervention for patients with stage IVA hepatocellular carcinoma without lymph node metastasis Ann Surg 227 1998 433 439
29. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
30. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
31. J.M. Llovet, S. Ricci, V. Mazzaferro SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
32. J.M. Llovet, J. Bustamante, and A. Castells Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1999 62 67
33. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
34. G.A. Omura, M.F. Brady, and H.D. Homesley Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 9 1991 1138 1150
35. S.J. Chang, R.E. Bristow, and H.S. Ryu Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer Ann Surg Oncol 19 2012 4059 4067